The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing advanced stages of prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for metastatic castration-resistant prostate cancer called Xtandi (enzalutamide). This new medication will soon be going through a national cancer drug review process that invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.
The survey will be available starting now and remain open until March 8, 2013.
Thank you for your participation.